We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > multiple myeloma

News List

REVLIMID® Approved by the European Commission as Monotherapy for the Maintenance Treatment of Patien americanpharmaceuticalreview
February 27, 2017
Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation announced that the European Commission (EC) has approved REVLIMID® (lenalidomide) as monotherapy for the maintenance treatment of adult patients with newly diagnosed multiple mye
Rabbit virus proves effective in treatment of multiple myeloma pharmafile
February 23, 2017
A team of researchers at the Medical University of South Carolina (MUSC) utilising the myxoma virus (MYXV) to treat multiple myeloma discovered that the method prompted a strong immune response and eliminated the majority of malignant cells associated wit
Health Canada approves REVLIMID plus dexamethasone as a first-line treatment for patients newly diag firstwordpharma
January 25, 2017
Celgene Inc. announced today that Health Canada has expanded the indication for REVLIMID® (lenalidomide capsules), in multiple myeloma.

Previous page 1 2 3 4 5 6 7 8 9 Next page